Filtering by:
Thyroid CancerFDA Approves Vitrakvi (Larotrectinib) for Tumors With Certain Genetic Change
For the second time, the US Food and Drug Administration (FDA) has approved a drug to treat tumors with a specific genetic change regardless of the type of cancer. Vitrakvi (larotrectinib) is for adults and children with solid tumors that test positive for NTRK genes, which can help cancerous tumors grow.
FDA Approves Drug Combination for Aggressive Type of Thyroid Cancer
The US Food and Drug Administration (FDA) has approved a combination of 2 targeted drugs to treat people with anaplastic thyroid cancer that has a certain type of gene mutation (BRAF V600E) and cannot be completely removed through surgery.
World Health Organization Links 8 More Cancer Types to Excess Weight
The International Agency for Research on Cancer (IARC), part of the World Health Organization, has added 8 types of cancer to those it had previously linked to being overweight or obese.
FDA Approves Lenvima (lenvatinib) for Thyroid Cancer
The US Food and Drug Administration (FDA) has approved Lenvima (linvatinib) for a type of thyroid cancer.